Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

If you’ve ever searched for ways to practice coding or prep for tech interviews, you’ve probably seen LeetCode mentioned ...

Recursion Pharmaceuticals announces a workforce reduction of approximately 20%. The Nvidia-backed company expects the move to extend its cash runway into the fourth quarter of 2027. Get more ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...